09/22/23 7:00 AMOTC : ACHFF clinical trialArch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT PeptideArch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced that it has submitted applications to the Ministry of Health (MoH) and local Ethics Committee in Turkey to obtain permission to proceed with a Phase IIRHEA-AInegative
06/27/23 7:15 AMOTC : ACHFF clinical trialArch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury TrialApproval from FDA to initiate Phase II trial with LSALT peptide to target cardiac surgery-associated acute kidney injury (CS-AKI) LSALT peptide targets dipeptidase-1 (DPEP-1), an enzyme known to mediate organ inflammation in the lungs, liver and kidneys There are currently no treatments availableRHEA-AInegative
04/18/23 7:10 AMOTC : ACHFF Arch Biopartners Announces Positive Results of Dose Escalation Human Trial for LSALT PeptideToday, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel therapeutics targeting organ inflammation, announced that it has safely increased the maximumRHEA-AIneutral
03/23/23 7:00 AMOTC : ACHFF Arch Biopartners Receives Funding for Development of LSALT Peptide Drug ProgramToday, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel therapeutics targeting organ inflammation, announced that Arch is receiving advisory services andRHEA-AIneutral
02/07/23 7:05 AMOTC : ACHFF Arch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney DiseaseToday, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of innovative technologies and novel therapeutics targeting organ inflammation, announced that an ArchRHEA-AIvery positive
10/05/22 7:20 AMOTC : ACHFF Arch Biopartners Adds Farris Smith as a Strategic AdvisorToday, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of innovative technologies and novel therapeutics targeting organ inflammation, welcomed Mr. Farris Smith ofRHEA-AIvery positive
08/05/22 7:30 AMOTC : ACHFF clinical trialArch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical TrialsArch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company targeting acute organ inflammation with novel therapeutics, announced today that the Company has added Dr. David Luke as a Strategic AdvisorRHEA-AIneutral
02/14/22 7:30 AMOTC : ACHFF covid-19Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)Arch Biopartners Inc. (“ArchRHEA-AIneutral
02/03/22 7:30 AMOTC : ACHFF Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate LSALT Peptide in the Prevention of Acute Kidney InjuryArch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that a scientific team led by Dr. Daniel Muruve at the University of Calgary, and their collaborators, have published a paper in the journal ScienceRHEA-AIneutral
01/04/22 7:25 AMOTC : ACHFF covid-19Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)Arch Biopartners Inc. (“ArchRHEA-AIneutral